Tahlil

Rapamycin (Sirolimus)(Rapamune®)

Sanal Hastane||1 dk okuma
Rapamycin (Sirolimus)(Rapamune®)

Klinik kullanımı

Otolog organ graftlarının tabii rejeksiyonunu baskılayan makrolid bir antibiyotiktir. Diğer immünosüpresanlardan farklı olarak antijenik ve sitokin (IL-2, IL-4, IL-15) stimülasyonuna cevap olarak görülen T lenfosit aktivasyonunu inhibe eder. Rapamycin, yüksek dozda uygulandığında hiperlipidemiye neden olur.

Referans değerler

3-20 ng/ml

 

#immunsüpresyon#nakil rejeksiyonu önleme#organ nakli

Kaynaklar ve Referanslar

  1. [1]Sehgal SN, Camardo JS, Scarola JA, et al. “Rapamycin (sirolimus, rapamune).”. Current opinion in nephrology and hypertension. 1995. PMID: 8591055. PubMed →
  2. [2]Abulail JA, Abu Husein S, Al-Tamimi M, et al.. “Impact of immunosuppressive therapy on non-melanoma skin cancer after solid organ transplantation: A critical systematic review.”. Transplant immunology. 2026. PMID: 41941970. PubMed →
  3. [3]Sehgal SN. “Rapamune (Sirolimus, rapamycin): an overview and mechanism of action.”. Therapeutic drug monitoring. 1995. PMID: 8588237. PubMed →
  4. [4]Foerster Y, Palaras J, Mayer K, Biedermann T, Persa OD. “Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.”. International journal of dermatology. 2026. PMID: 41546605. PubMed →
  5. [5]Kaeberlein TL, Green AS, Haddad G, et al. “Evaluation of off-label rapamycin use to promote healthspan in 333 adults.”. GeroScience. 2023. PMID: 37191826. PubMed →
  6. [6]Fernandes Lucas S, Warner S, North-Lewis P, et al.. “Long Term Outcomes and Safety Profile of Sirolimus in Post Liver Transplant Children.”. Pediatric transplantation. 2025. PMID: 41354973. PubMed →
Paylaş:
← Tüm Makaleler